Clinical Trials Logo

Clinical Trial Summary

The purpose of this registry is to evaluate the safety and efficacy of RIC for patients with symptomatic intracranial atherosclerotic stenosis (sICAS) undergoing endovascular therapy.


Clinical Trial Description

Intracranial atherosclerotic stenosis (ICAS) is one of the leading causes of ischemic stroke, and its incidence varies widely among different ethnic groups. ICAS may represent approximately 10% of ischemic stroke in Caucasians and even be responsible for up to 50% in Chinese population. Recurrent stroke risks are as high as 23% 1 year after transient ischemic stroke (TIA) or stroke in patients with a stenosis of 70% or more. The Chinese IntraCranial AtheroSclerosis (CICAS) study indicated the prevalence of ICAS was 46.6%; Patients with ICAS had more severe stroke at admission and stayed longer in hospitals compared with those without intracranial stenosis. After 12 months, recurrent stroke occurred in 3.27% of patients with no stenosis, in 3.82% for those with 50% to 69% stenosis, in 5.16% for those with 70% to 99% stenosis, and in 7.27% for those with total occlusion. Current guidelines recommend best medical treatment (BMM) for patients with sICAS, which contains antithrombotic therapy, management of vascular risk factor (diabetes, lipids, and especially hypertension) and patient behaviors modification (diet, exercise and smoking cessation). But, even with the intervention of BMM, the recurrence of ischemic stroke or transient ischemic attacks (TIAs) in patients with sICAS still cannot be reduced. Endovascular therapy with intracranial angioplasty and/or stenting holds great promise as a treatment for sICAS. A recent trial found that, compared with bare-metal stent, drug-eluting stent reduced the risks of In-stent restenosis and ischemic stroke recurrence in patients with sICAS. However, endovascular therapy for patients with sICAS is known to be associated with potentially serious complications such as cerebral hyper-perfusion syndrome, intracranial hemorrhage, embolism and In-stent restenosis, etc. Those are the main reasons that affect the effect of endovascular therapy, thus limiting its application and popularization to a great degree. Remote Ischemic Conditioning (RIC) is one of the most potent neuroprotective approaches that can minimize neuronal damage by protecting against ischemia-reperfusion injury and promote neuronal recovery by stimulating endogenous protective mechanism through transiently occluding the blood supply to non-significant organs or tissues such as limbs. The investigators see a promising future for RIC in facilitating further clinical translation and application due to its unique features of safety, simplicity and non-invasiveness. In recent years, the safety and efficacy of RIC on stroke intervention has been confirmed by a series of basic and clinical researches, among which RIC in combination with adjuvant drug therapy for sICAS-induced ischemic stroke patient improve cerebral blood flow and reduce stroke recurrence. Since its safety and efficacy has been verified, RIC can also be used to reduce the risks of In-stent restenosis for patients with carotid stent implantation and has extensive application prospects for patients with severe acute ischemic stroke treated with endovascular thrombectomy. There is not enough evidence as to provide any specific recommendation regarding the use of RIC in sICAS patients, But we speculate that RIC has a certain effect on preventing perioperative complications for patients with sICAS undergoing endovascular therapy. Therefore, we intend to conduct this prospective cohort study to shed light on the utility of this promising therapy. This study prospectively collects data of patients with sICAS who receive endovascular therapy in the Comprehensive Neurovascular Ward of Tianjin Huanhu Hospital. Depending on their preference, patients enrolled in this registry will be divided into 2 groups, receiving either endovascular therapy alone or endovascular therapy plus RIC respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05653505
Study type Observational [Patient Registry]
Source Tianjin Huanhu Hospital
Contact Ming Wei, PhD
Phone 13502182903
Email drweiming@163.com
Status Not yet recruiting
Phase
Start date January 1, 2023
Completion date July 1, 2026

See also
  Status Clinical Trial Phase
Completed NCT01235286 - Cutaneous Remote Ischemic Preconditioning in Plastic Surgery N/A
Completed NCT01118000 - Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning N/A
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Recruiting NCT03380663 - Conditioning Based Intervention Strategies N/A
Completed NCT03023150 - Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation - Froedtert N/A
Completed NCT02981680 - Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery N/A
Completed NCT00821522 - The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery Phase 1
Active, not recruiting NCT01164618 - The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response Phase 2
Not yet recruiting NCT05957523 - Effects of Remote Ischemic Preconditioning on Components of Peripheral Blood and Gut Microbiome (EMINENT) N/A
Completed NCT04887610 - Factors That Influence Blood Vessel Regulation During Exercise in Humans N/A
Completed NCT05219344 - Tissue Flossing and Lower Limb Neuromuscular Function N/A
Completed NCT00453531 - Model System for Transient Forearm Blood Vessel Dysfunction Phase 1/Phase 2
Not yet recruiting NCT05412888 - Effect of CoQ10 on the Endocrine Function of Skeletal Muscle N/A
Recruiting NCT03900390 - The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient N/A
Completed NCT02411266 - Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage N/A
Completed NCT02666235 - Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR) Phase 2
Terminated NCT01743937 - A Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans Phase 4
Completed NCT04016857 - Remote Ischemic Preconditioning During Lower Limb Revascularization N/A
Completed NCT02965547 - Remote Ischemic Preconditioning of Dynamic Cerebral Autoregulation in Healthy Adults N/A
Completed NCT05350683 - Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR Phase 2